# A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies

> **NCT02354417** · PHASE1 · TERMINATED · sponsor: **Fate Therapeutics** · enrollment: 3 (actual)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **BIOLOGICAL:** Biological: ProHema-CB

## Key facts

- **NCT ID:** NCT02354417
- **Lead sponsor:** Fate Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2016-12
- **Final completion:** 2017-02
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2018-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02354417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02354417, "A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02354417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*